THREAD Lands $50M for Decentralized Clinical Trial Research Platform

What You Must Know:

— enhance its capabilities and provide 24 × 7 international, multilingual client support;.

— rapidly execute and develop COVID-19 medical trial threat mitigation tools to advance important research study throughout the pandemic;.

— totally decentralized research studies tailored to their specific research study requires in essential therapeutic locations.

< Recent Traction/Milestones. Decentralized Clinical Trial Research Platform. To. date, THREAD has supported more than 100 decentralized research studies. The. business will continue to buy broadening and boosting its ingenious. platform and supporting services as a growing list of the worlds leading. pharmaceutical and life science companies engage the company as their. partner for their scientific research studies.. -- include new features to its proprietary, configurable decentralized research study platform;. -- eventually support customers with virtual sees, hybrid decentralized research studies. -- broaden its international footprint to more than 40 nations;. THREAD is a leading service provider of a proprietary, decentralized research study platform and suite of supporting services used by biopharma, CROs, and life science companies to remotely catch information from participants and websites during, in-between, and in lieu of in-clinic visits. THREADs platform and supporting services are helping consumers to minimize study launch timelines, lower study budget plans with Virtual Visits, and bring studies from the center to clients homes. THREAD offers key platform features such as eConsent, eCOA/ePRO, sensing units, tips, and telehealth Virtual Visits to support remote data capture, hybrid virtual research studies, and totally decentralized studies in essential restorative locations. -- THREAD is an ingenious innovation and service service provider that increases individual engagement by allowing pharmaceutical business and agreement research organizations to from another location catch data from participants and sites throughout, in between and in lieu of in-clinic sees.. Over the past year, THREAD has leveraged the health care companies combined pharmaceutical proficiency, a network of industry resources and capital to:. THREAD, an ingenious innovation and company that enables. decentralized scientific research, announced today that its speeding up the. companys growth after getting an additional capital dedication of up to. $ 50 million from tactical healthcare investors, Water Street Healthcare. Partners and JLL Partners. In 2019, Water Street and JLL Partners. purchased and obtained THREAD to more broaden and develop THREADs offering on a global. scale. The companys newest capital infusion develops on a year of. significant growth and investments in its platform and services to advance. decentralized research study methods for large-scale, Phase Ib-- IV global. medical trials. -- This significant financial investment comes at a time of incredible. growth for the business, which has actually broadened its footprint to 40 countries in the. past year. Even more, its cutting edge, virtual method has actually allowed. pharmaceutical business and researchers alike to continue with critical. medical trials throughout the pandemic. -- THREAD gets additional $50 million capital commitment from Water Street and JLL Partners to expand its decentralized clinical trial research study platform